Zobrazeno 1 - 10
of 611
pro vyhledávání: '"Ho Yeong, Lim"'
Autor:
Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park
Publikováno v:
Gut and Liver, Vol 18, Iss 1, Pp 116-124 (2024)
Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in Sout
Externí odkaz:
https://doaj.org/article/785dff6945e744c09e895390ae02284a
Autor:
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Publikováno v:
Liver Cancer (2024)
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD
Externí odkaz:
https://doaj.org/article/3da67a4e9b81471598019e46c12fc527
Autor:
Nalee Kim, Jeong Il Yu, Hee Chul Park, Jung Yong Hong, Ho Yeong Lim, Myung Ji Goh, Yong-Han Paik
Publikováno v:
Journal of Liver Cancer, Vol 23, Iss 2, Pp 350-361 (2023)
Background/Aim Patients with large (>5 cm) hepatocellular carcinoma (HCC) have limited treatment options, thus necessitating the identification of prognostic factors and the development of predictive tools. This study aimed to identify prognostic fac
Externí odkaz:
https://doaj.org/article/bbe0547ad2184a9a89d905555482bd36
Autor:
Shukui Qin, Weijia Fang, Zhenggang Ren, Shuangyan Ou, Ho Yeong Lim, Feng Zhang, Kin Chung Lee, Hye Jin Choi, Jiandong Tong, Min Tao, Aibing Xu, Ashley Cheng, Chang-Hsien Lu, Chang-Fang Chiu, Mohamed Ibrahim Abdul Wahid, Shital Kamble, Josephine M. Norquist, Wenyan Zhong, Chen Li, Zhendong Chen
Publikováno v:
Liver Cancer (2024)
Introduction KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular
Externí odkaz:
https://doaj.org/article/af000c83c7e94d4da9def0a30952f917
Autor:
Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/1a80d93b46254b83bfdf5d4c0de1a368
Autor:
Sun Young Jeong, Jung Yong Hong, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Jae Yeon Jang, Youngkyung Jeon, Seung Tae Kim
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. Objectives: There are limite
Externí odkaz:
https://doaj.org/article/0bb07600025f4925b23ab1ee1ce2d3fc
Autor:
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Publikováno v:
Liver Cancer (2023)
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall surviva
Externí odkaz:
https://doaj.org/article/cd768b0d783a455fbb086706dc35b886
Autor:
Jung Yong Hong, Hee Jin Cho, Jason K. Sa, Xiaoqiao Liu, Sang Yun Ha, Taehyang Lee, Hajung Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hee Chul Park, Tae Wook Kang, Hyunchul Rhim, Su Jin Lee, Razvan Cristescu, Jeeyun Lee, Yong Han Paik, Ho Yeong Lim
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-15 (2022)
Abstract Background A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods Herein, we performed comprehensive molecular characterization of immediat
Externí odkaz:
https://doaj.org/article/9436a920f67a4275b778a98aec3608cb
Autor:
Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek-Yeol Ryoo, Philippe Merle, Joong-Won Park, Jean-Frederic Blanc, Ho Yeong Lim, Albert Tran, Yi-Wah Chan, Paul McAdam, Evelyn Wang, Ann-Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou-Alfa
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Introduction: Cabozantinib, an inhibitor of MET, AXL, and VEGF receptors, significantly improved overall survival (OS) and progression-free survival (PFS) versus placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). In
Externí odkaz:
https://doaj.org/article/a9aecdc91b464f2abd10eaa8419833fa
Autor:
Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim, Baek-Yeol Ryoo, Min-Hee Ryu, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok-Bog Moon, Ki-Hoon Kim, Tae Won Kim, Jeong Seok Lee, Richard S. Finn, June-Young Koh, Changhoon Yoo
Regorafenib plus nivolumab (RegoNivo) combination has shown promising anti-cancer activity in multiple cancer types. REBNOBATE trial is a single-arm multicenter phase 2 trial of first-line RegoNivo in patients (pts) with uHCC (NCT04310709). Here we r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e24ad3eff16aefcb685092da825f8c7